• Citer

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

par Raymond, Éric E.;Faivre, Sandrine;Alexandre, Jérôme;Goldwasser, François;Besse-Hammer, Tatiana;Awada, Ahmad ;Gianella-Borradori, Athos;Jego, V.;Trandafir, Lucia;Rejeb, Narmyn
Référence Investigational new drugs, 32, 1, page (94-103)
Publication Publié, 2014

Article révisé par les pairs

• Détails
• Contenu

Titre:	A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
Auteur:	Raymond, Éric E.; Faivre, Sandrine; Alexandre, Jérôme; Goldwasser, François; Besse-Hammer, Tatiana; Awada, Ahmad; Gianella-Borradori, Athos; Jego, V.; Trandafir, Lucia; Rejeb, Narmyn
Informations sur la publication:	Investigational new drugs, 32, 1, page (94-103)
Statut de publication:	Publié, 2014
Sujet CREF:	Cancérologie
	Pharmacologie
Mots-clés:	Aurora kinase inhibitor
	Mitosis
	MSC1992371A
	Neutropenia
	Phase l
	Targeted therapy
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Agents -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
	Demography
	Deoxycytidine -- analogs & derivatives
	Dose-Response Relationship, Drug
	Drug Administration Schedule
	Female
	Humans
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- blood -- drug therapy
	Norbornanes -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
	Protein Kinase Inhibitors -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
	Pyrimidines -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
	Young Adult
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6997
	info:doi/10.1007/s10637-013-9950-y
	info:scp/84899076412
	info:pmid/23539344